The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody

Introduction. High prevalence of migraine and its impact on quality of life requires the development of original agents. In 2020, fremanezumab, a new calcitonin gene-related peptide monoclonal antibody was authorized in Russia. Objective: to evaluate safety and effectiveness of fremanezumab in pa...

Full description

Bibliographic Details
Main Authors:	Larisa A. Dobrynina, Maksim A. Afanasev, Anastasia V. Belopasova, Maria V. Gubanova, Ekaterina V. Baydina
Format:	Article
Language:	English
Published:	Research Center of Neurology 2023-06-01
Series:	Анналы клинической и экспериментальной неврологии
Subjects:	migraine monoclonal antibodies cgrp fremanezumab clinical practice
Online Access:	https://annaly-nevrologii.com/journal/pathID/article/viewFile/934/pdf

Similar Items

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019-04-01)

Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
by: Kimberly D. Mackenzie, et al.
Published: (2022-11-01)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
by: Piero Barbanti, et al.
Published: (2022-04-01)

Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
by: Tulsi Shah, et al.
Published: (2023-03-01)

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?
by: Sena Uzun, et al.
Published: (2023-05-01)

Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
by: Michail Vikelis, et al.
Published: (2023-07-01)

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
by: Suruchi Aditya, et al.
Published: (2023-01-01)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
by: Simona Sacco, et al.
Published: (2019-01-01)

Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials
by: Stephen D. Silberstein, et al.
Published: (2021-01-01)

Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
by: Stephanie J. Nahas, et al.
Published: (2021-11-01)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
by: Maurice T. Driessen, et al.
Published: (2022-05-01)

Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023-04-01)

Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review
by: Theodoros Mavridis, et al.
Published: (2019-01-01)

Glycerol Trinitrate Acts Downstream of Calcitonin Gene-Related Peptide in Trigeminal Nociception—Evidence from Rodent Experiments with Anti-CGRP Antibody Fremanezumab
by: Nicola Benedicter, et al.
Published: (2024-03-01)

Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
by: Andreas A. Argyriou, et al.
Published: (2023-04-01)

Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
by: Jean Schoenen, et al.
Published: (2023-08-01)

Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
by: Egilius L. H. Spierings, et al.
Published: (2021-04-01)

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
by: Piero Barbanti, et al.
Published: (2023-03-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
by: Abouch V. Krymchantowski, et al.
Published: (2023-03-01)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor
by: Hans-Christoph Diener, et al.
Published: (2020-04-01)

The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
by: Birgit Vogler, et al.
Published: (2023-08-01)

The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
by: Min Hou, et al.
Published: (2017-04-01)

Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine
by: Giulia Ceccardi, et al.
Published: (2023-11-01)

Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison
by: Jiajie Lu, et al.
Published: (2021-05-01)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
by: Bianca Raffaelli, et al.
Published: (2023-01-01)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
by: Casper Emil Christensen, et al.
Published: (2018-11-01)

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
by: Maurice T. Driessen, et al.
Published: (2022-04-01)

Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE
by: Richard B. Lipton, et al.
Published: (2023-11-01)

Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
by: Peter Holzer, et al.
Published: (2022-01-01)

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
by: Licia Grazzi, et al.
Published: (2024-02-01)

Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study
by: Eleonora De Matteis, et al.
Published: (2022-09-01)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
by: Michal Fila, et al.
Published: (2023-01-01)

Serum CGRP in migraine patients using erenumab as preventive treatment
by: Simone de Vries Lentsch, et al.
Published: (2022-09-01)

Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway
by: Zifan Zhou, et al.
Published: (2023-11-01)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
by: Andreas A. Argyriou, et al.
Published: (2022-12-01)

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
by: Antun R. Pavelic, et al.
Published: (2022-12-01)

Potential use of microRNA-590 biomarkers verses plasma calcitonin gene-related peptide for diagnosis of migraine
by: Hany Mohamed El Deeb, et al.
Published: (2024-02-01)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
by: Edoardo Caronna, et al.
Published: (2021-10-01)